

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jun 2026

### Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

#### Protocol summary

##### Study aim

Synthesis of sodium zirconium cyclosilicate (SZC-9) drug by different methods and its in vitro comparison with the brand sample available in the market (Lokelma).

##### Design

A clinical trial with 2 parallel intervention groups and no control group, double-blind, phase 2, on 48 patients and randomized by using the website QuickCalcs.

##### Settings and conduct

This study will be conducted on two series of patient volunteers. The first group will receive a sample sachet (test) and the second group will receive a brand sachet. Blood samples are taken by the clinical supervisor immediately after taking the drug, and the sample preparation steps are performed on them to analyze the amount of analyte. This study will be conducted in Imam Reza Hospital, Tabriz.

##### Participants/Inclusion and exclusion criteria

Patients volunteers with hyperkalaemia, both sexes, ages ranged from 22 to 75 years, para-clinical health based on the tests performed, and no history of diseases affecting the digestive system.

##### Intervention groups

The intervention group received single-dose SZC-9 sachet formulated in this study and the control group received single-dose brand tablets (Lokelma®) manufactured by the company (AstraZeneca).

##### Main outcome variables

Level of blood potassium concentration

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130313012810N11**  
Registration date: **2023-07-15, 1402/04/24**

Registration timing: **prospective**

Last update: **2023-07-15, 1402/04/24**

Update count: **0**

##### Registration date

2023-07-15, 1402/04/24

##### Registrant information

###### Name

Hamed Hamishehkar

###### Name of organization / entity

Drug Applied Research Center, Tabriz University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 41 1336 3311

###### Email address

hamishehkar.hamed@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2024-08-31, 1403/06/10

##### Expected recruitment end date

2024-10-31, 1403/08/10

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

## Public title

Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

## Purpose

Other

## Inclusion/Exclusion criteria

### Inclusion criteria:

patients with hyperkalemia Volunteers aged 22-75 years male and female

### Exclusion criteria:

History of diseases affecting the digestive system Taking any medication at least 1 week before the start of the study

## Age

From **22 years** old to **75 years** old

## Gender

Both

## Phase

Bioequivalence

## Groups that have been masked

- Participant
- Care provider

## Sample size

Target sample size: **24**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Web-based randomization is used by using the website <http://www.graphpad.com/quickcalcs/index.cfm> Candidates will be given codes 1 to 48 in the order of entering the study, so that when the selection of candidates begins, the first person who enters the study will have code 1 and the last candidate who enters the study will have code 48. Then the following steps will be done on the site: Random numbers>>>Randomly assign subjects to groups>>>Randomly choose a group for each subject. And finally, two groups A and B will be randomly composed of 24 volunteers each.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

In this study, the volunteers participating in the study and the clinical supervisor are blinded to the type of product consumed at each time of the study (test or reference product). That is, the product outside the original packaging will be given to the volunteer by the researcher for consumption

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

## 1

### Ethics committee

#### Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

#### Street address

Daneshgah St. Drug Applied Research Center

#### City

Tabriz

#### Province

East Azarbaijan

#### Postal code

5165665811

### Approval date

2023-03-06, 1401/12/15

### Ethics committee reference number

IR.TBZMED.REC.1401.1098

## Health conditions studied

## 1

### Description of health condition studied

Hyperkalaemia

### ICD-10 code

E87.5

### ICD-10 code description

Hyperkalaemia

## Primary outcomes

## 1

### Description

Plasma concentration of potassium

### Timepoint

Measurement of blood potassium at the beginning of the study (before the start of the intervention), 2, 6, 12, 24, 36, and 48 hours after receiving the drug by the patients

### Method of measurement

Biorexfars potassium kit

## Secondary outcomes

empty

## Intervention groups

## 1

### Description

Intervention group 1: Candidates will receive 10 grams of powder (sachet) of the test drug and blood will be taken 48 hours after receiving the drug

### Category

N/A

## 2

### Description

Intervention group 2: Candidates will receive 10 grams of

powder (sachet) of the brand drug and blood will be taken 48 hours after receiving the drug

**Category**

N/A

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Drug Applied Research Center, Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

**Phone**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Parviz Shahabi

**Street address**

Research and Technology Vice-Chancellor., Central Building No. 2., 3rd Floor., Tabriz University of Medical Sciences., Golgasht Street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5165990001

**Phone**

+98 41 3336 4664

**Email**

shahabip@tbzmed.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Position**

professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

**Phone**

+98 41 3336 3181

**Fax**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Web page address**

<http://darc.tbzmed.ac.ir/>

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Position**

professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Drug Applied Research Center, Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

**Phone**

+98 41 3336 3181

**Fax**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Web page address**

<http://darc.tbzmed.ac.ir/>

**Phone**

+98 41 3336 3181

**Fax**

+98 41 3336 3311

**Email**

hamishehkar.hamed@gmail.com

**Web page address**

<http://darc.tbzmed.ac.ir/>

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Hamed Hamishehkar

**Position**

professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Drug Applied Research Center, Tabriz University of  
Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

51656-65811

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available